In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 34, No. 4_suppl ( 2016-02-01), p. 715-715
Kurzfassung:
715 Background: UPMC CancerCenter (UPMC) and Indiana University Health (IUH) utilize Via Pathways (VP) for their CP initiative. VP are developed and maintained by disease committees that evaluate therapies on merit of efficacy, then toxicity, and finally cost (if efficacy and toxicity are comparable) to provide a recommendation for specific patient presentations. Recent data from key studies regarding the use of panitumumab (PAN) or cetuximab (CET) in the setting of metastatic colo-rectal cancer by the colo-rectal committee led to the determination that both treatments were equally effective with no significant difference in toxicity (Price et al., 2014; Peeters et al., 2014). A subsequent cost comparison utilizing CMS average sales prices demonstrated an approximate 14% monthly cost advantage for PAN. A substitution of PAN for CET across all metastatic lines of therapy in the pathway was initiated as of August 2014. This analysis was undertaken to understand the impact of this change. Methods: We reviewed the UPMC and IUH data within the VP database to compare new treatment starts of CET and PAN before and after this change was put in place. Results: There was rapid change in the selection behavior between the two drugs as demonstrated in the table. Conclusions: The results in this simple example of substituting equivalent drugs based on cost exemplify the power of CP to rapidly change prescribing habits across two large cancer networks. CP serve as an invaluable tool to allow oncology practices to quickly respond to the changing treatment norms of oncology care. [Table: see text]
Materialart:
Online-Ressource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2016.34.4_suppl.715
Sprache:
Englisch
Verlag:
American Society of Clinical Oncology (ASCO)
Publikationsdatum:
2016
ZDB Id:
2005181-5
